Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes

Frontiers in Physiology
Ian SteinkeRajesh H Amin

Abstract

Diabetes mellitus exists as a comorbidity with congestive heart failure (CHF). However, the exact molecular signaling mechanism linking CHF as the major form of mortality from diabetes remains unknown. Type 2 diabetic patients display abnormally high levels of metabolic products associated with gut dysbiosis. One such metabolite, trimethylamine N-oxide (TMAO), has been observed to be directly related with increased incidence of cardiovascular diseases (CVD) in human patients. TMAO a gut-liver metabolite, comes from the metabolic degenerative product trimethylamine (TMA) that is produced from gut microbial metabolism. Elevated levels of TMAO in diabetics and obese patients are observed to have a direct correlation with increased risk for major adverse cardiovascular events. The pro-atherogenic effect of TMAO is attributed to enhancing inflammatory pathways with cholesterol and bile acid dysregulation, promoting foam cell formation. Recent studies have revealed several potential therapeutic strategies for reducing TMAO levels and will be the central focus for the current review. However, few have focused on developing rational drug therapeutics and may be due to the gaps in knowledge for understanding the mechanism by which micro...Continue Reading

References

Jan 1, 1990·Pharmacology & Therapeutics·R Ayesh, R L Smith
Nov 1, 1987·Clinical Pharmacology and Therapeutics·M Al-WaizR L Smith
Sep 1, 1986·Digestive Diseases and Sciences·G L Simon, S L Gorbach
Mar 1, 1994·Toxicology and Applied Pharmacology·R N HinesD M Ziegler
Jan 1, 1993·Annual Review of Pharmacology and Toxicology·D M Ziegler
Jun 1, 1997·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·C G NaceK M Crofton
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·John R Cashman, Jun Zhang
Feb 14, 2006·The American Journal of Clinical Nutrition·Peter Libby
Feb 21, 2006·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Tímea BorbásKároly Tihanyi
Jun 17, 2006·Proceedings of the National Academy of Sciences of the United States of America·Subramaniam EswaramoorthySubramanyam Swaminathan
Sep 21, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Tímea BorbásJohn R Cashman
Jan 17, 2007·Archives of Dermatology·Gehan ArseculeratneJames Ferguson
Aug 28, 2007·Journal of Biochemical and Molecular Toxicology·Jun ZhangJohn R Cashman
Apr 22, 2008·Trends in Pharmacological Sciences·Ian R Phillips, Elizabeth A Shephard
Mar 27, 2009·Molecular Genetics and Metabolism·Meike S MotikaJohn R Cashman
Apr 9, 2010·Nature Medicine·Gökhan S Hotamisligil
Dec 31, 2010·International Journal of Cardiology·Anja SandekMathias Rauchhaus
Feb 13, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jennifer L PluznickMichael J Caplan
Feb 26, 2013·Nature Reviews. Microbiology·Felix Sommer, Fredrik Bäckhed
May 24, 2014·ACS Chemical Biology·Smaranda CraciunEmily P Balskus
Dec 24, 2014·Cell Host & Microbe·Rachel N CarmodyPeter J Turnbaugh
Mar 3, 2015·Current Nutrition Reports·Xavier Pi-Sunyer
Jun 13, 2015·European Heart Journal·Ele Ferrannini, Ralph A DeFronzo
Jul 15, 2015·Current Opinion in Clinical Nutrition and Metabolic Care·E Angela MurphyKyle M Herbert
Feb 20, 2016·Circulation Research·Martin R BennettGary K Owens
Mar 18, 2016·Current Medical Research and Opinion·Kristy IglaySwapnil Rajpathak
Apr 14, 2016·Journal of Internal Medicine·T Arora, F Bäckhed
Oct 21, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Diede FennemaElizabeth A Shephard
May 28, 2016·Scientific Reports·Elko RandrianarisoaNorbert Stefan
Jun 23, 2016·The New England Journal of Medicine·Herbert Tilg
Oct 22, 2016·Cell Chemical Biology·Smaranda BodeaCatherine L Drennan
Sep 28, 2016·JAMA : the Journal of the American Medical Association·Michael G SilvermanMarc S Sabatine
Nov 12, 2016·Toxins·Manuel T VelasquezDominic S Raj

❮ Previous
Next ❯

Citations

Nov 26, 2021·Applied Biochemistry and Biotechnology·Shivani Singhal, Vibha Rani

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.